Cargando…

Omicron severity: milder but not mild

Detalles Bibliográficos
Autores principales:	Nealon, Joshua, Cowling, Benjamin J
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier Ltd. 2022
Materias:	Comment
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8769661/ https://www.ncbi.nlm.nih.gov/pubmed/35065007 http://dx.doi.org/10.1016/S0140-6736(22)00056-3

Ejemplares similares

Omicron infection milder in nursing home residents
por: Katz, Morgan J, et al.
Publicado: (2022)

Milder disease with Omicron: is it the virus or the pre-existing immunity?
por: Sigal, Alex
Publicado: (2022)

Why is the SARS-CoV-2 Omicron variant milder?
por: Xia, Bingqing, et al.
Publicado: (2022)

Estimating disease severity of Omicron and Delta SARS-CoV-2 infections
por: Sigal, Alex, et al.
Publicado: (2022)

Omicron in pregnancy: time to breathe easier?
por: Auger, Nathalie, et al.
Publicado: (2022)

Neuroinflammation in mild respiratory COVID-19: insights into cognitive impairment in milder cases
por: Li, Qian, et al.
Publicado: (2022)

Milder is better? advantages and disadvantages of "mild" ovarian stimulation for human in vitro fertilization
por: Revelli, Alberto, et al.
Publicado: (2011)

Prioritisation of COVID-19 boosters in the omicron era
por: Irving, Stephanie A, et al.
Publicado: (2022)

How repeated influenza vaccination effects might apply to COVID-19 vaccines
por: Thompson, Mark G, et al.
Publicado: (2022)

Assessing the potential for fomite transmission of SARS-CoV-2
por: Short, Kirsty R, et al.
Publicado: (2023)

Omicron: fewer adverse outcomes come with new dangers
por: Post, Lori Ann, et al.
Publicado: (2022)

Lower risk of Multi-system inflammatory syndrome in children (MIS-C) with the omicron variant
por: Lopez, Laura, et al.
Publicado: (2022)

Number needed to vaccinate for COVID-19 booster doses: a valuable metric to inform vaccination strategies
por: Feng, Shuo, et al.
Publicado: (2023)

Omicron breakthrough infections in patients with immune-mediated inflammatory diseases
por: Liew, Jean W, et al.
Publicado: (2022)

Effectiveness of mRNA booster doses against the omicron variant
por: Zedan, Hadeel T, et al.
Publicado: (2022)

COVID-19 vaccine boosters in the Asia-Pacific region in the context of Omicron
por: Hart, John D, et al.
Publicado: (2022)

Pathogenicity of SARS-CoV-2 Omicron BA.1.1 in hamsters
por: Chan, Jasper Fuk-Woo, et al.
Publicado: (2022)

COVID-19 vaccine effectiveness against the omicron (BA.2) variant in England
por: Kirsebom, Freja C M, et al.
Publicado: (2022)

The potential of Beta variant containing COVID booster vaccines for chasing Omicron in 2022
por: Sridhar, Saranya, et al.
Publicado: (2022)

SARS-CoV-2 spread and hospitalisations in paediatric patients during the omicron surge
por: Belay, Ermias D, et al.
Publicado: (2022)

Vaccination and protective immunity to SARS-CoV-2 omicron variants in people with immunodeficiencies
por: Nadesalingam, Angalee, et al.
Publicado: (2023)

The benefit of vaccination after previous SARS-CoV-2 infection in the omicron era
por: Boaventura, Viviane S, et al.
Publicado: (2023)

Bivalent omicron (BA.1) booster vaccination against SARS-CoV-2
por: Vasin, Andrey V, et al.
Publicado: (2023)

Could Beta variant containing COVID-19 booster vaccines tackle Omicron variants?
por: Jin, Pengfei, et al.
Publicado: (2023)

Impairment of Cerebrovascular Hemodynamics in Patients With Severe and Milder Forms of Sickle Cell Disease
por: Afzali-Hashemi, Liza, et al.
Publicado: (2021)

SARS-CoV-2 in Malaysia: A surge of reinfection during the predominantly Omicron period
por: Yang, Su Lan, et al.
Publicado: (2022)

Neutralizing antibodies and their cocktails against SARS-CoV-2 Omicron and other circulating variants
por: Yang, Yang, et al.
Publicado: (2022)

Omicron SARS-CoV-2 variant: a new chapter in the COVID-19 pandemic
por: Karim, Salim S Abdool, et al.
Publicado: (2021)

Durability of AZD1222 and hybrid humoral immunity against omicron BA.1 and BA.4
por: Soto-Rifo, Ricardo
Publicado: (2023)

Rational use of face masks in the COVID-19 pandemic
por: Feng, Shuo, et al.
Publicado: (2020)

New year, new SARS-CoV-2 variant: Resolutions on genomic surveillance protocols to face Omicron
por: Oróstica, Karen Y., et al.
Publicado: (2022)

Effectiveness of the COVID-19 vaccines against hospitalisation with Omicron sub-lineages BA.4 and BA.5 in England
por: Møller Kirsebom, Freja Cordelia, et al.
Publicado: (2022)

GPs should not try to detect mild COPD
por: Enright, Paul, et al.
Publicado: (2020)

Therapierefraktäre Hypernatriämie bei milder COVID-19
por: Künzler, T., et al.
Publicado: (2021)

SARS-CoV-2 breakthrough infections in patients with immune-mediated inflammatory diseases during the omicron dominant period
por: Boekel, Laura, et al.
Publicado: (2022)

Shedding new light on COVID-19 therapeutics during the omicron era: a deeper dive into real-world data
por: De Vito, Andrea, et al.
Publicado: (2023)

Real-world effectiveness of nirmatrelvir–ritonavir against BA.4 and BA.5 omicron SARS-CoV-2 variants
por: Wong, Carlos K H, et al.
Publicado: (2023)

Updated report of COVID-19 vaccine safety monitoring in Japan: booster doses for Omicron variants and vaccinations for infants and young children
por: Yamaguchi, Toshihiro, et al.
Publicado: (2023)

What do we know about pathological mechanism and pattern of lung injury related to SARS-CoV-2 Omicron variant?
por: Scendoni, Roberto, et al.
Publicado: (2023)

Azithromycin: can its benefit be ruled out in mild COVID-19?
por: Rodríguez-Molinero, Alejandro
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_lhh9trgfki5977t9oemkcvm4tf